- Recommendation ID
- TA854/01
- Question
Further research is recommended to help address remaining clinical and cost-effectiveness uncertainties for esketamine, summarised in section 3.36.
- Any explanatory notes
(if applicable) Further research is recommended in the wider clinical area of depression on:
• how clinical data from regulatory trials in depression could appropriately be used in health technology assessment and decision modelling
• the natural history and long-term course of treatment-resistant depression and health-related quality of life in the long-term
• characterising the healthcare resource use of people with depression, including exploring which people use services like hospitals and crisis resolution home teams.
Source guidance details
- Comes from guidance
- Esketamine nasal spray for treatment-resistant depression
- Number
- TA854
- Date issued
- December 2022
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 31/12/2022 |